Preferred Label : ceritinib;
MeSH synonym : 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
UNII : K418KG2GET;
InChIKey : VERWOWGGCGHDQE-UHFFFAOYSA-N;
Origin ID : C586847;
UMLS CUI : C3818721;
ATC code(s)
- CISMeF manual mappings
- Exact mapping(s) to DCI
- ceritinib [International Nonproprietary Name]
- MeSH indexing information
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- ceritinib [International Nonproprietary Name]
https://www.has-sante.fr/jcms/p_3244195/fr/zykadia-cbnpc
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic agents
protein kinase inhibitors
receptor Protein-Tyrosine kinases
ceritinib
administration, oral
bronchial neoplasms
carcinoma, non-small-cell lung
ALK gene rearrangement positive
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
ceritinib
pyrimidines
sulfones
pyrimidines
sulfones
---
https://www.has-sante.fr/portail/jcms/c_2888462/fr/zykadia
2018
false
false
false
France
administration, oral
evaluation of the transparency committee
Zykadia
ceritinib
pyrimidines
sulfones
---
https://www.has-sante.fr/portail/jcms/c_2887771/fr/zykadia
2018
false
false
false
France
evaluation of the transparency committee
Zykadia
ceritinib
pyrimidines
sulfones
---
https://ansm.sante.fr/informations-de-securite/ceritinib-zykadia-r-150-mg-gelule-nouvelle-posologie-recommandee-dinitiation-du-traitement
2018
false
false
false
France
French
guidelines for drug use
pharmacovigilance note
administration, oral
ceritinib
patient education handout
antineoplastic agents
carcinoma, non-small-cell lung
ceritinib
product surveillance, postmarketing
pyrimidines
sulfones
---
https://www.has-sante.fr/portail/jcms/c_2824816/fr/zykadia
https://www.has-sante.fr/portail/jcms/c_2824816/fr/zykadia-ceritinib-inhibiteur-de-tyrosine-kinase
2017
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
ceritinib
ceritinib
ceritinib
adult
Advanced Malignant Neoplasm
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
ALK gene rearrangement positive
insurance, health, reimbursement
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
protein-tyrosine kinases
survival analysis
guidelines for drug use
Tyrosine Kinase Inhibitors
pyrimidines
sulfones
pyrimidines
sulfones
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-ALK-crizotinib-ceritinib
2016
false
false
false
France
French
guidelines for drug use
protein kinase inhibitors
crizotinib
carcinoma, non-small-cell lung
ceritinib
ceritinib
receptor Protein-Tyrosine kinases
antineoplastic agents
administration, oral
protein kinase inhibitors
ceritinib
Drug-Related side effects and adverse reactions
continuity of patient care
drug interactions
interdisciplinary communication
risk factors
drug monitoring
ceritinib
carcinoma, non-small-cell lung
ALK gene rearrangement positive
ALK protein, human
patients guideline
practice guideline
Tyrosine Kinase Inhibitors
pyrimidines
sulfones
pyrimidines
sulfones
pyrimidines
sulfones
receptor Protein-Tyrosine kinases
Crizotinib
Crizotinib
Crizotinib
Anaplastic Lymphoma Kinase
---
http://www.has-sante.fr/portail/jcms/c_2569228/fr/zykadia
http://www.has-sante.fr/portail/jcms/c_2569228/fr/zykadia-ceritinib-inhibiteur-de-tyrosine-kinase
2015
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
ceritinib
ceritinib
ceritinib
adult
Advanced Malignant Neoplasm
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
ALK gene rearrangement positive
insurance, health, reimbursement
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
protein-tyrosine kinases
survival analysis
guidelines for drug use
Tyrosine Kinase Inhibitors
pyrimidines
sulfones
pyrimidines
sulfones
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase
---
https://www.ema.europa.eu/medicines/human/EPAR/Zykadia
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
ceritinib
drug approval
europe
pyrimidines
pyrimidines
sulfones
sulfones
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
receptor Protein-Tyrosine kinases
adult
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
administration, oral
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ceritinib
ceritinib
Tyrosine Kinase Inhibitors
Anaplastic Lymphoma Kinase
---
